benign prostatic hyperplasia lower urinary tract symptoms nonalcoholic fatty liver disease prostate cancer prostatic diseases

Systematic Review Meta-analysis Holmium Laser Enucleation of Prostate Transurethral Resection of Prostate Benign Prostatic Hyperplasia

Prostatic Arterial Embolization Benign Prostate Hyperplasia Lower Urinary Tract Symptoms Meta-Analysis

膀胱肿瘤 化学疗法，癌，局部灌注 温度

alcohol bladder cancer dose-response meta-analysis systematic review commercial or financial relationships that could be construed as a potential conflict of interest.

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/pathology Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Humans Neoplasm Metastasis Neoplasm Staging Practice Guidelines as Topic Randomized Controlled Trials as Topic Urinary Bladder Neoplasms/*drug therapy/pathology Immune checkpoint inhibitors Platinum-based chemotherapy Survival outcomes Treatment guidelines Urothelial carcinoma funded this work. MK PK and SD are employees of Evidera.

Cystectomy Humans Neoplasm Recurrence Local/surgery Prospective Studies *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures bladder cancer repeat restaging second look transurethral resection

5 alpha reductase inhibitors androgen deprivation therapy androgen receptor bladder cancer

Diabetes Mellitus Type 2/complications/drug therapy Humans Hypoglycemic Agents/*adverse effects/therapeutic use Odds Ratio Pioglitazone/*adverse effects/therapeutic use Randomized Controlled Trials as Topic Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*etiology Bladder cancer dose-response relationship meta-analysis pioglitazone

Adjuvants Immunologic/*therapeutic use Administration Intravesical BCG Vaccine/*therapeutic use Carcinoma Transitional Cell/pathology/*therapy Cystoscopy Female Humans Male Multivariate Analysis Muscle Smooth/*pathology Neoplasm Invasiveness Neoplasm Recurrence Local/*epidemiology Proportional Hazards Models Sex Factors Survival Rate Urinary Bladder Neoplasms/pathology/*therapy *Urologic Surgical Procedures Bladder cancer Gender differences Local recurrence Meta-analysis Transurethral resection of bladder tumor

Biomarkers Tumor/*urine Humans Prognosis Urinary Bladder Neoplasms/*diagnosis/*urine Biomarker Bladder cancer Diagnosis Systematic review Urine

Administration Intravesical Antineoplastic Agents/*pharmacology Humans Maintenance Chemotherapy/*methods Neoplasm Invasiveness Neoplasm Recurrence Local/*prevention & control Prognosis Randomized Controlled Trials as Topic Treatment Outcome *Urinary Bladder Neoplasms/drug therapy/pathology Bladder cancer Chemotherapy Intravesical Maintenance

Administration Intravesical Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects BCG Vaccine/administration & dosage Bayes Theorem Deoxycytidine/administration & dosage/analogs & derivatives Disease Progression Epirubicin/administration & dosage Female Humans Isoniazid/administration & dosage Male Middle Aged Mitomycin/administration & dosage Neoplasm Invasiveness Neoplasm Recurrence Local Odds Ratio Randomized Controlled Trials as Topic Risk Factors Time Factors Treatment Outcome Urinary Bladder Neoplasms/*drug therapy/mortality/pathology Gemcitabine efficacy and safety intravesical therapy non-muscle invasive bladder cancer tumor progression tumor recurrence